tirzepatide nash phase 3 Tirzepatide: First Approval | Drugs Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis

20,21 The confirmatory secondary end point (controlled for multiple comparisons) was an improvement of at least one fibrosis stage and no worsening of NASH (with worsening defined as an increase of 1 point in either the lobular inflammation score or the hepatocyte ballooning score according to the NASH Clinical Research Network criteria) after 72 weeks

However, you should always consult a healthcare professional to establish a weight loss regimen

PMCID: PMC12530271

We have a wide selection of general medical supplies, including solutions for irrigation and injection, clear and amber vials, needles, syringes, personal protective equipment (PPE), disposables, OTC medication and much more